AFC-HD AMS Life Science Co., Ltd. provided earnings guidance for the year ending August 2023. For the period, the company expects net sales of ¥24,741 million, Operating profit of ¥1,481 million, and Profit attributable to owners of the parent of ¥687 million or ¥48.82 basic per share.